Kori Wallace

Inserm — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index3.9kcitations88works45.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(66), Microscopic Colitis(40), Eosinophilic Esophagitis(31), Immunodeficiency and Autoimmune Disorders(20), Autoimmune and Inflammatory Disorders Research(8)

Publications88 total

Risankizumab for Ulcerative Colitis
JAMA·2024· 93 citedOpen Access
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
New England Journal of Medicine·2024· 127 citedOpen Access
O23 Risankizumab vs ustekinumab for patients with moderate-to-severe crohn’s disease: results from the phase 3b SEQUENCE study
Oral Presentations·2024
984 RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND STUDY
Gastroenterology·2024· 1 cited
OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
Journal of Crohn s and Colitis·2024· 16 citedOpen Access
Risankizumab: Mechanism of action, clinical and translational science
Clinical and Translational Science·2024· 36 citedOpen Access
S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial
The American Journal of Gastroenterology·2023· 12 cited
S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
The American Journal of Gastroenterology·2023· 3 cited
Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease
Clinical Therapeutics·2023· 9 citedOpen Access
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial
Journal of Crohn s and Colitis·2023· 14 citedOpen Access
S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
The American Journal of Gastroenterology·2023· 6 cited
1593 FRAILTY AND OUTCOMES FOR OLDER PATIENTS TREATED IN A MAJOR TRAUMA CENTRE
Age and Ageing·2023Open Access
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
PharmacoEconomics - Open·2023· 14 citedOpen Access
O58 Risankizumab therapy in crohn’s patients results in sustained improvements in endoscopic outcomes: FORTIFY post-hoc analysis
Oral Presentations·2023
Investigation of liver-targeted peripheral focused ultrasound stimulation (pFUS) and its effect on glucose homeostasis and insulin resistance in type 2 diabetes mellitus: a proof of concept, phase 1 trial
QJM·2023· 12 citedOpen Access
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
Advances in Therapy·2023· 12 citedOpen Access
117 - 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
Gastroenterología y Hepatología·2023
S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy
The American Journal of Gastroenterology·2022· 1 cited
Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 <scp>MOTIVATE</scp>, <scp>ADVANCE</scp> and <scp>FORTIFY</scp> clinical trials
Alimentary Pharmacology & Therapeutics·2022· 26 citedOpen Access
S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction
The American Journal of Gastroenterology·2022
page 1 of 5Next →

Frequent Co-authors

Ezequiel Neimark(20), Remo Panaccione(17), Geert D’Haens(15), Marc Ferrante(15), Edward V. Loftus(14), Anne Robinson(12), W. Rachel Duan(12), Jasmina Kalabic(12), Peter Bossuyt(11), Silvio Danese(11), William J. Sandborn(11), Stefan Schreiber(11), Brian G. Feagan(11), Laurent Peyrin‐Biroulet(11), Alexandra Song(11), Xiaomei Liao(10), Julián Panés(9), Kristina Kligys(9), Sofie Berg(9), Alessandro Armuzzi(8)